AxoGen (NASDAQ:AXGN) Now Covered by Analysts at Raymond James

Stock analysts at Raymond James assumed coverage on shares of AxoGen (NASDAQ:AXGN) in a research note issued on Monday, Briefing.com reports. The brokerage set an “outperform” rating and a $13.00 price target on the medical equipment provider’s stock. Raymond James’ target price would indicate a potential upside of 79.56% from the company’s previous close.

AXGN has been the topic of several other research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price objective on shares of AxoGen in a research report on Thursday, June 20th. StockNews.com cut AxoGen from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.25.

AxoGen Trading Up 0.3 %

Shares of AxoGen stock opened at $7.24 on Monday. AxoGen has a 12-month low of $3.45 and a 12-month high of $10.83. The business’s 50 day moving average is $6.65 and its 200-day moving average is $7.81. The company has a quick ratio of 2.23, a current ratio of 3.43 and a debt-to-equity ratio of 0.72. The stock has a market cap of $316.46 million, a P/E ratio of -14.48 and a beta of 1.11.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. AxoGen had a negative return on equity of 22.18% and a negative net margin of 12.99%. The business had revenue of $41.38 million for the quarter, compared to analysts’ expectations of $42.05 million. Equities research analysts predict that AxoGen will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of AxoGen

Large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its holdings in shares of AxoGen by 534.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,805 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 6,575 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in AxoGen in the third quarter valued at about $83,000. Lazard Asset Management LLC boosted its stake in AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after buying an additional 2,671 shares in the last quarter. SG Americas Securities LLC boosted its stake in AxoGen by 45.9% in the fourth quarter. SG Americas Securities LLC now owns 14,823 shares of the medical equipment provider’s stock valued at $101,000 after buying an additional 4,666 shares in the last quarter. Finally, Sentry Investment Management LLC acquired a new stake in AxoGen in the fourth quarter valued at about $131,000. 80.29% of the stock is owned by institutional investors and hedge funds.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.